THIOTHIXENE HYDROCHLORIDE INTENSOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE INTENSOL (THIOTHIXENE HYDROCHLORIDE INTENSOL).
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
| Metabolism | Extensively metabolized in the liver via sulfoxidation, N-demethylation, and N-oxidation. Involves CYP450 enzymes, primarily CYP1A2. |
| Excretion | Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine. |
| Half-life | Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation. |
| Protein binding | >95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 10-20 L/kg, indicating extensive tissue distribution and accumulation in peripheral compartments. |
| Bioavailability | Oral: >90% (well absorbed but undergoes first-pass metabolism, resulting in approximately 50-60% bioavailability); Intramuscular: 100% bioavailable. |
| Onset of Action | Oral: 2-6 hours; Intramuscular: 30-60 minutes; Onset may be delayed in some patients. |
| Duration of Action | Oral: Effects last 12-24 hours, with antipsychotic effects persisting for days after discontinuation; Intramuscular: 4-6 hours for acute effects. |
| Molecular Weight | 443.9 |
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
| Dosage form | CONCENTRATE |
| Renal impairment | No specific GFR-based dose adjustments are recommended; use with caution in renal impairment due to potential accumulation. |
| Liver impairment | Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use or reduce dose by 50-75%. |
| Pediatric use | For children >12 years: Initial 2 mg three times daily; titrate to 15-30 mg/day in divided doses. Maximum 60 mg/day. Safety/efficacy in <12 years not established. |
| Geriatric use | Initial dose: 1-2 mg twice daily; titrate slowly. Lower maintenance doses (e.g., 10-20 mg/day) recommended due to increased sensitivity. |
| 1st trimester | Thiothixene crosses the placenta. First trimester exposure may be associated with a small increased risk of congenital malformations, particularly cardiovascular defects. Use only if benefit clearly outweighs risk. |
| 2nd trimester | Risk of extrapyramidal symptoms and withdrawal in neonate after third trimester exposure. Limited data suggest potential for adverse effects on fetal growth and development. Use with caution. |
| 3rd trimester | Avoid in third trimester due to risk of neonatal extrapyramidal symptoms, withdrawal, and possible respiratory depression. If exposure occurs, monitor neonate for abnormal muscle movements and agitation. |
Clinical note
Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE INTENSOL (THIOTHIXENE HYDROCHLORIDE INTENSOL).
| Placental transfer | Thiothixene crosses the human placenta. Animal studies show placental transfer; human data confirm measurable levels in cord blood and amniotic fluid. Degree is likely moderate based on molecular weight and lipophilicity. |
| Breastfeeding |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Thiothixene is not approved for the treatment of dementia-related psychosis.
| Serious Effects |
Hypersensitivity to thiothixene or any componentsCNS depression (e.g., severe alcoholism, barbiturate or narcotic intoxication)Comatose statesCirculatory collapse
| Precautions | Increased mortality in elderly patients with dementia-related psychosis, Tardive dyskinesia, Neuroleptic malignant syndrome (NMS), QT prolongation and risk of arrhythmias, Seizures, Leukopenia, neutropenia, and agranulocytosis, Orthostatic hypotension, Hyperprolactinemia, Temperature dysregulation, Anticholinergic effects |
| Food/Dietary | Avoid alcohol. Thiothixene may cause drowsiness; alcohol can worsen this effect. No specific food restrictions, but maintaining a balanced diet is recommended. Grapefruit juice has no known interaction. |
Loading safety data…
| Thiothixene is excreted into human milk in low concentrations. The American Academy of Pediatrics considers thiothixene compatible with breastfeeding, but long-term effects on neurodevelopment are unknown. Monitor infant for sedation, irritability, and feeding difficulties. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Thiothixene is a typical antipsychotic of the thioxanthene class. Data on teratogenicity in humans are limited. In the first trimester, there is a potential for malformations, though a specific pattern has not been established. Second and third trimester exposure may be associated with extrapyramidal symptoms and/or withdrawal symptoms in the neonate, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. The risk is considered low to moderate. |
| Fetal Monitoring | Monitor the mother for therapeutic response and adverse effects such as extrapyramidal symptoms, sedation, hypotension, and QTc prolongation. Fetal/neonatal monitoring should include assessment for extrapyramidal symptoms, withdrawal symptoms, and adaptation after delivery. Consider neonatal ECG if maternal QTc prolongation is present. |
| Fertility Effects | Thiothixene may increase prolactin levels, potentially leading to galactorrhea, amenorrhea, and anovulation in women, and decreased libido or gynecomastia in men. These effects may impair fertility. The impact is reversible upon discontinuation. |
| Clinical Pearls | Thiothixene is a typical antipsychotic with high potency; dose titration should be gradual to minimize extrapyramidal symptoms (EPS). Use the lowest effective dose, especially in elderly patients due to increased sensitivity. Monitor for tardive dyskinesia, neuroleptic malignant syndrome, and QTc prolongation. The oral concentrate must be diluted before administration. |
| Patient Advice | Take thiothixene exactly as prescribed. Do not stop suddenly without consulting your doctor. · Dilute the oral concentrate in water, juice, or other suitable beverage before taking. · Avoid alcohol and other central nervous system depressants. · Report any unusual movements, stiffness, fever, or confusion to your healthcare provider immediately. · This medication may cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you. · Use sun protection as thiothixene may increase sensitivity to sunlight. |